This educational activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.
Management of Newly Diagnosed Chronic Lymphocytic Leukemia Patients
Sandra E. Kurtin, RN, MS, AOCN®, ANP-C
The University of Arizona Cancer Center
Chronic lymphocytic leukemia (CLL), a B-cell lymphoproliferative disorder, is one of the most common forms of leukemia. It can present as indolent disease or aggressive, rapidly progressive disease. This activity will provide an overview of the epidemiology, signs and symptoms, diagnostic work-up, immunohistochemistry, flow cytometry, and clinical staging of CLL. Understanding the complexity and characteristics of CLL will equip advanced practitioners with the knowledge necessary for the clinical management of newly diagnosed CLL patients.
Relapsed or Refractory Chronic Lymphocytic Leukemia and the Management of Chronic Lymphocytic Leukemia Patients Treated With Immunotherapy
Supportive Care in Chronic Lymphocytic Leukemia
Risk-Stratified Treatment in Chronic Lymphocytic Leukemia
What test should an advanced practitioner order if CLL is suspected?
What are the differences in the side effect profile between the monoclonal antibody treatments for CLL?
What are the most important prognostic factors in CLL?
How does Bruton's tyrosine kinase differ from other tyrosine kinases, and what role does it play in CLL and treatment?
The monoclonal antibodies rituximab, obinutuzumab, and ofatumumab all target CD20; how do they differ in their indications in the treatment of CLL?
What should advanced practitioners look for with CLL patients that also have lymphocytosis?
Bone Marrow Biopsy Demonstration Video